Johnson & Johnson MedTech Launches Major Leap in AFib Treatment

Published: 10 Jul 2025

Author: Precedence Research

Share :

Johnson & Johnson MedTech has unveiled its Varipulse pulsed field ablation (PFA) platform in the Asia-Pacific region, marking a significant milestone in the management of atrial fibrillation (AFib). The innovative platform offers a novel energy modality for catheter ablation, enabling more defined and selective tissue ablation with reduced collateral damage. With its integration into the advanced Carto 3 System of the firm, which is an electroanatomical, 3-dimensional cardiac mapping technology, the Varipulse platform enables ablation and mapping within a single workflow with a unified interface. Such a combination enables physicians to visualize cardiac structures in real time, thereby increasing the precision and reproducibility of the procedure and enhancing clinical efficiency.

The Varipulse platform should provide a new approach to overcoming the shortcomings of existing thermal ablation-based systems, which rely on extreme temperatures to isolate heart tissue that causes AFib. Alternatively, PFA utilizes elevated-power, brief-duration electrical impulses that alter cardiac cells without severely impacting adjacent structures, such as the esophagus, pulmonary veins, and phrenic nerve. The platform is further positioned to work with deep or conscious sedation, providing versatility for different clinical environments and patient types.

FDA approval was granted to the system in November 2024, and expansion has continued into international markets. A significant frontier for this technology lies in the Asia-Pacific region, where demand for cardiovascular interventions is growing at a rapid pace. The launch facilitates the treatment of AFib in countries such as Japan, Australia, Singapore, and others in the region. This decision also demonstrates the overarching ambition of Johnson & Johnson MedTech to increase the availability of advanced cardiac procedures in emerging markets within the medical industry. The ever-growing number of elderly people and the development of arrhythmias still provide clinical opportunities, fueling market expansion.

Executive’s Statement:

Jing Li, Vice President, Electrophysiology & Neurovascular, Johnson & Johnson MedTech, Asia Pacific:

“The introduction of the Varipulse platform in the Asia-Pacific region marks a significant advancement towards our goal of transforming atrial fibrillation care. The adoption of the platform can demonstrate the unique value of integration with Carto 3D to enhance efficiencies in the workflow of AFib treatment and improve patient outcomes.”